Regenxbio annual gross margin
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Regenxbio's gross margin was 88.09% for fiscal 2025.
View full Regenxbio company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 88.09% | +28.37 pp |
| 2024 | 2024-12-31 | 59.72% | +0.95 pp |
| 2023 | 2023-12-31 | 58.76% | +7.15 pp |
| 2022 | 2022-12-31 | 51.61% | −37.37 pp |
| 2021 | 2021-12-31 | 88.98% | +12.09 pp |
| 2020 | 2020-12-31 | 76.89% | +0.28 pp |
| 2019 | 2019-12-31 | 76.61% | −18.98 pp |
| 2018 | 2018-12-31 | 95.59% | +12.03 pp |
| 2017 | 2017-12-31 | 83.56% | −14.31 pp |
| 2016 | 2016-12-31 | 97.86% | −0.84 pp |
| 2015 | 2015-12-31 | 98.71% | +0.70 pp |
| 2014 | 2014-12-31 | 98.01% | +0.85 pp |
| 2013 | 2013-12-31 | 97.16% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 99.04% | +23.42 pp |
| Q1 2026 | 2026-03-31 | −73.22% | — |
| Q4 2025 | 2025-12-31 | 80.46% | +10.24 pp |
| Q3 2025 | 2025-09-30 | 80.75% | +31.94 pp |
| Q2 2025 | 2025-06-30 | 75.61% | +23.06 pp |
| Q4 2024 | 2024-12-31 | 70.22% | +20.81 pp |
| Q3 2024 | 2024-09-30 | 48.81% | −8.35 pp |
| Q2 2024 | 2024-06-30 | 52.55% | −0.02 pp |
| Q1 2024 | 2024-03-31 | 72.58% | −5.93 pp |
| Q4 2023 | 2023-12-31 | 49.41% | −9.81 pp |
| Q3 2023 | 2023-09-30 | 57.16% | +6.54 pp |
| Q2 2023 | 2023-06-30 | 52.57% | −7.76 pp |
| Q1 2023 | 2023-03-31 | 78.51% | +49.25 pp |
| Q4 2022 | 2022-12-31 | 59.22% | −35.00 pp |
| Q3 2022 | 2022-09-30 | 50.61% | −3.55 pp |
| Q2 2022 | 2022-06-30 | 60.33% | +4.89 pp |
| Q1 2022 | 2022-03-31 | 29.26% | −45.05 pp |
| Q4 2021 | 2021-12-31 | 94.22% | +42.05 pp |
| Q3 2021 | 2021-09-30 | 54.16% | −28.28 pp |
| Q2 2021 | 2021-06-30 | 55.44% | −16.29 pp |
| Q1 2021 | 2021-03-31 | 74.31% | −6.37 pp |
| Q4 2020 | 2020-12-31 | 52.17% | −15.61 pp |
| Q3 2020 | 2020-09-30 | 82.45% | −0.59 pp |
| Q2 2020 | 2020-06-30 | 71.73% | −3.82 pp |
| Q1 2020 | 2020-03-31 | 80.68% | −16.04 pp |
| Q4 2019 | 2019-12-31 | 67.79% | −25.24 pp |
| Q3 2019 | 2019-09-30 | 83.03% | −7.22 pp |
| Q2 2019 | 2019-06-30 | 75.55% | −14.78 pp |
| Q1 2019 | 2019-03-31 | 96.72% | −1.46 pp |
| Q4 2018 | 2018-12-31 | 93.03% | — |
| Q3 2018 | 2018-09-30 | 90.26% | −9.74 pp |
| Q2 2018 | 2018-06-30 | 90.33% | −9.58 pp |
| Q1 2018 | 2018-03-31 | 98.18% | — |
| Q3 2017 | 2017-09-30 | 100.00% | +17.60 pp |
| Q2 2017 | 2017-06-30 | 99.91% | +1.97 pp |
| Q4 2016 | 2016-12-31 | 100.18% | +0.29 pp |
| Q3 2016 | 2016-09-30 | 82.40% | −13.74 pp |
| Q2 2016 | 2016-06-30 | 97.94% | −0.89 pp |
| Q1 2016 | 2016-03-31 | 92.37% | −2.51 pp |
| Q4 2015 | 2015-12-31 | 99.89% | — |
| Q3 2015 | 2015-09-30 | 96.14% | −1.38 pp |
| Q2 2015 | 2015-06-30 | 98.83% | — |
| Q1 2015 | 2015-03-31 | 94.88% | — |
| Q3 2014 | 2014-09-30 | 97.52% | — |
Over the last five fiscal years, Regenxbio's gross margin increased from 76.89% to 88.09%, a change of +11.20 percentage points. The latest reported quarter, Q2 2026, shows 99.04%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Regenxbio source filings ↗